Emergence of multidrug-resistant Salmonella enterica serovar Typhi with reduced susceptibility to fluoroquinolones in Cambodia☆
Received 29 July 2009; accepted 2 September 2009. published online 05 October 2009.
Abstract
From December 2006 to April 2009, we conducted an etiology study among Cambodian patients presenting with acute fever of unknown origin. Salmonella enterica serovar Typhi was detected in 0.9% (41/4985) blood cultures. Antimicrobial susceptibility testing showed decreased susceptibility to ampicillin (56% resistant; MIC90, >256 μg/mL), chloramphenicol (56% resistant; MIC90, >256 μg/mL), trimethoprim/sulfamethoxazole (56% resistant; MIC90, >256 μg/mL), nalidixic acid (81% resistant; MIC90, not defined), ciprofloxacin (0% resistant; MIC90, 0.5 μg/mL), and ceftriaxone (0% resistant; MIC90, 0.094 μg/mL). Multidrug resistance, defined as antimicrobial resistance to ampicillin, chloramphenicol, and trimethoprim/sulfamethoxazole, was found in 56% of the isolates, and 80% had reduced susceptibility to ciprofloxacin (defined as MIC ≥0.12 μg/mL).
aUS Naval Medical Research Unit No. 2, Jakarta, Indonesia 10560
bNational Institute of Public Health, Ministry of Health, Phnom Penh, Cambodia 12152
cUS Naval Medical Research Unit No. 2, Phnom Penh, Cambodia 12152
Corresponding author. US Embassy Jakarta, FPO AP 96520, Indonesia. Tel.: +62-21-421-4457; fax: +62-21-428-73658.
☆ Disclosure: Views expressed in this article are those of the authors and do not reflect the official policy of the government of Cambodia, Cambodian Ministry of Health, Cambodian NIPH, the US Department of Defense, Department of the Navy, or US NAMRU2 Phnom Penh, Cambodia.
ABSTRACT